Press release
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
Double-digit percentage revenue and patient count growth in full-year 2021 Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022
About this update from United Therapeutics Corporation
[{"type":"text","content":"\nDouble-digit percentage revenue and patient count growth in full-year 2021\n\nCompany reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022\n\nMajor amendment to Tyvaso DPI™ NDA pushes FDA decision date to May 2022\n\n SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2021. Full year total revenues rose to $1,686 million, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2021.\n\n“We continue to make strong progress with patient growth as we march toward our target of reaching 25,000 patients with our therapies by the end of 2025,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “The recent transplants of our xenoheart and xenokidney products demonstrate the tremendous potential of our business model for the second half of the 2020s and beyond. Indeed, Mr. David Bennett, Sr., the first UHeart™ recipient, continues to have strong cardiovascular function seven weeks after his transplant.”\n\n“Our commercial teams continue to perform with double-digit percentage growth in revenue and patient counts in 2021 compared to 2020,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “Despite a setback with Tyvaso DPI, we remain on track to achieve 6,000 patients with Tyvaso by the end of 2022.”\n\nUnited Therapeutics recently received an information request letter from the U.S. Food and Drug Administration (FDA) requesting additional information regarding the pulmonary safety of Tyvaso DPI related to a pending Citizen's Petition. United Therapeutics responded to the agency’s information request; however, the FDA has considered this response to be a major amendment to the NDA, extending FDA’s review deadline to May 2022.\n\nFOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS\n\nKey financial highlights include (in millions, except per share data):\n\n\n\n \n\n\n\nThree Months Ended\nDecember 31,\n\n\n\n \n\n\n\nYear Ended\nDecember 31,\n\n\n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n2020\n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n2020\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n...